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Martin G. Myers Jr., MD, PhD, received the American Diabetes
Association’s prestigious 2010 Outstanding Scientiﬁc Achieve-
ment Award at the Association’s 70th Scientiﬁc Sessions in
Orlando, Florida, on 28 June 2010. The Outstanding Scientiﬁc
Achievement Award recognizes outstanding scientiﬁc achieve-
ment in the ﬁeld of diabetes, taking into consideration indepen-
dence of thought and originality.
Currently the Marilyn H. Vincent Professor of Diabetes Research
at the University of Michigan, Ann Arbor, and Associate Profes-
sor in internal medicine and in molecular and integrative physi-
ology at the University of Michigan Medical School, Dr. Myers
began his impressive track record in diabetes research as a
graduate student in the laboratory of Dr. Morris White at the
Joslin Diabetes Center/Harvard Medical School. There, Dr. Myers
deciphered many of the insulin signaling pathways engaged by
insulin receptor substrate proteins.
Following his graduation from the Harvard MD-PhD Program in
1997, Dr. Myers was promoted to instructor in medicine at the
Joslin Diabetes Center/Harvard Medical School. He began his
independent work by building a molecular framework for under-
standing the mechanisms of leptin signaling, including how
individual phosphorylation sites on the leptin receptor recruit
distinct signaling molecules. He was promoted to assistant
professor at Harvard in 1999.
In 2004, Dr. Myers moved to the University of Michigan, where he
built upon the molecular framework of leptin signaling to probe
the regulation of metabolism by individual leptin signals. Dr.
Myers’ laboratory revealed the speciﬁcity of leptin signals in
metabolic control, including the role for leptin-STAT3 signaling
in the regulation of energy balance and glucose homeostasis. His
group also deﬁned roles for leptin receptor feedback inhibition
and hypothalamic mTor signaling in metabolism.
Dr. Myers’ laboratory has recently developed novel molecular
approaches to elucidate the leptin-regulated brain circuits that
contribute to metabolic control, enabling the discovery of novel
brain systems and their functions.
In 1998, Dr. Myers received the American Diabetes Association’s
Career Development Award for his scientiﬁc abilities. Dr. Myers’
current support includes the National Institute of Diabetes and
Digestive and Kidney Diseases MERIT Award. Diabetes 59:
2708–2714, 2010
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he scientiﬁc tale that I share in this article
actually began decades ago, with the discovery
of two independent mutant mouse strains at the
Jackson Laboratory. The obese (ob/ob) and dia-
betic (db/db) strains suffer from an identical set of prob-
lems: they are obese, they have type 2 diabetes, and a
variety of their endocrine systems are disrupted in a
pattern reminiscent of the response to starvation.
Early studies, also carried out at the Jackson Labora-
tory, predicted that the gene affected in the ob/ob mouse is
a hormone, while the receptor for that hormone is dis-
rupted in db/db mice. Indeed, when the ob gene was cloned
by the laboratory of Jeff Friedman 15 years ago, it was
found to encode a hormone, which was named “leptin.”
Leptin is produced by fat cells. To a reasonable approx-
imation, the more energy (fat) is stored in a fat cell, the
more leptin the cell produces and secretes into the circu-
lation. Circulating leptin makes its way to the brain, where
it binds to the leptin receptor. Subsequent to the identiﬁ-
cation of leptin, the cloning of the leptin receptor revealed
that this gene was disrupted in db/db mice.
Different parts of the brain mediate distinct functions,
and only a few parts of the brain express the leptin
receptor. As one might expect, the leptin receptor is
expressed at particularly high levels in the hypothalamus,
which is the region of the brain that controls a great deal
of food intake, glucose homeostasis, and endocrine func-
tion. Leptin action via leptin receptors in the brain sup-
presses appetite and hepatic glucose production (thereby
modulating the amount of glucose in the blood). Leptin
also signals that the long-term energy stores in fat sufﬁce
to permit the utilization of energy on energy-intensive
endocrine functions, including reproduction. Falling leptin
levels mediate the response to fasting; fasting decreases
the amount of energy stored as triglyceride in fat cells,
thus decreasing the amount of circulating leptin. This
reduction in leptin receptor signaling therefore increases
the drive to eat, increases hepatic glucose production
(helping to support blood glucose levels during the fast),
and diminishes the permissive action of leptin on endo-
crine function.
Mutation of the genes encoding leptin or its receptor
promotes a similar response. In the absence of the leptin
receptor signal in db/db mice, for instance, the brain
cannot sense the leptin signal. This leads to increased
appetite and decreased restraint on hepatic glucose pro-
duction. The increase in appetite stimulates feeding,
thereby expanding fat mass and leading to obesity, along
with high leptin levels. In the absence of the leptin
receptor, however, these elevated leptin levels cannot be
sensed and so accomplish nothing. The lack of leptin-
mediated restraint on hepatic glucose production in db/db
mice also predisposes to diabetes—especially in the pres-
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obesity. The lack of leptin receptor signaling also de-
creases endocrine function, resulting in infertility and the
disruption of other energy-requiring endocrine systems.
The animal acts as though it is starved, even though fat
stores are high, simply because it cannot perceive that the
fat stores exist in the absence of leptin receptor signaling.
The central, overarching question that represents the
focus of my laboratory is, how does leptin work? We are
approaching this question in two ways. First, what are the
cellular mechanisms of leptin receptor signaling and how
do speciﬁc leptin receptor signals control energy balance
and glucose homeostasis? Second, on what set or sets of
neurons in the brain does leptin act to control energy
balance and glucose homeostasis?
Because I was trained by Morris White, who received
the Lilly Award in 1999 for his discoveries in cellular
insulin receptor signaling, it was natural for my laboratory
to follow the footsteps that Morris White had laid down in
studying insulin signaling and to apply the same principles
to the leptin receptor. This article does not show all of the
data that helped us to work out these pathways; Fig. 1
summarizes the leptin receptor signaling pathways that
our lab and others have worked out thus far, however.
The leptin receptor operates as a preformed dimer; it is
an integral membrane protein with an extracellular hor-
mone-binding domain and an intracellular signaling do-
main. The leptin receptor does not contain any intrinsic
enzymatic activity, but relies on an associated tyrosine
kinase (Jak2) for signaling. When leptin binds the recep-
tor, it partially activates Jak2, which then autophosphory-
lates, further increasing the activity of the Jak2 kinase.
The fully activated Jak2 then phosphorylates three
tyrosine residues on the intracellular domain of the leptin
receptor. Each of these tyrosine residues lies in a distinct
amino acid motif and recruits a unique set of downstream
signaling partners. Tyr1138 binds to a latent transcription
factor STAT3, which is then phosphorylated by Jak2.
Phosphorylated STAT3 translocates to the nucleus, where
it controls gene expression. Tyr1077 recruits a similar
transcription factor, STAT5, which is likewise phosphory-
lated and translocated to the nucleus to regulate the
expression of other genes. Tyr985 binds to two proteins.
First, it binds to SHP2, which also becomes tyrosine
phosphorylated; this promotes the activation of the extra-
cellular signal–related kinase (ERK) kinase signaling cas-
cade. Second, STAT3 signaling increases the expression of
a protein called the suppressor of cytokine signaling 3
(SOCS3), and SOCS3 binds to Tyr985. The binding of
SOCS3 to Tyr985 inhibits Jak2, thus shutting down all of
leptin receptor signaling in a process called “feedback
inhibition.”
Hence, we regard the leptin receptor as having essen-
tially four “inception” points from which spring speciﬁc
downstream signals—Jak2, Tyr985 and SHP2/SOCS3,
Tyr1077 and STAT5, and Tyr1138 and STAT3. Combined,
these four signals mediate all of leptin action on energy
balance, glucose homeostasis, and endocrine function.
Building upon this understanding of how the leptin
receptor operates in the cell, we next set out to determine
the role for each individual leptin receptor signal in
leptin actions in intact animals. Our approach to this issue
has been to mutate speciﬁc signaling sites on the leptin
receptor and determine what the resultant mutant recep-
tors can and cannot do when expressed in mice. By
mutating a particular motif on the leptin receptor, we
block a speciﬁc downstream signal; if we do this in an
intact animal, we can study the animals to determine what
the signal in question has to do with the regulation of
physiology. For instance, if we mutate a signal that is
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FIG. 1. Leptin receptor signaling pathways. Letters following phosphorylation sites represent subsequent amino acids, using the single-letter
codes. See text for details.
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we would expect that mice with this mutant receptor will
be obese and diabetic.
In doing this, it is important to take into account that the
leptin receptor is expressed only in a few select places in
the brain. Figure 2 shows a cross-section of the mouse
brain, with the leptin receptor–expressing cells shown in
white. Leptin controls feeding but has little impact on
volitional movement (such as wiggling your pinky ﬁnger),
and while the leptin receptor is not expressed in the motor
cortex, the brain area that controls motor function, it is
expressed in the hypothalamus, although only in the
subset of cells that have to do with energy balance and
metabolism.
Because it is important that we express the mutant
leptin receptors in the right places and at the right levels
in the brain—that is, not in the motor cortex, but in the
speciﬁc cells of the hypothalamus that express the
leptin receptor—we decided to use a gene replacement
strategy to put the mutant receptors into mice. Essen-
tially, we swapped the mutant leptin receptor gene into
the spot in the genome that is occupied by the endoge-
nous leptin receptor gene. Thus, the mutant leptin
receptor is expressed at the same levels and in the same
neurons as the normal receptor would be in regular
mice. Here, I discuss six types of mice, each expressing
different variations on the leptin receptor (Fig. 3).
The ﬁrst type is the normal animal, which we call wild
type (WT). These mice have normal leptin receptors with
the full complement of leptin receptor signals. We also
have db/db mice, which possess a mutant leptin receptor
that is missing all known signaling motifs, and thus cannot
send any downstream signals.
Next, we have Delta/Delta mice that express what we
call the delta receptor. This receptor is truncated right
after the Jak2 interaction site and is missing all of the
leptin receptor tyrosine phosphorylation sites. Thus, this
receptor can signal via the receptor-associated Jak2 only.
Additionally, we generated a series of mutant receptors
that contain single point mutations, each of which disrupts
a particular phosphorylation site and the downstream
signals controlled by that site. In the ﬁrst of these, we
mutated Tyr985 to block the recruitment of SHP2 and
SOCS3. In the second, we mutated Tyr1077 to block the
recruitment of STAT5. The last of these contains a muta-
tion of Tyr1138, thus blocking the binding of STAT3 to the
leptin receptor.
The ﬁrst set of studies discussed here is a comparison of
normal, WT mice with db/db mice that have no leptin
receptor and Delta/Delta mice whose leptin receptor sig-
nals by Jak2 only. We initially examined the body weight
of these animals to determine whether Jak2 signaling
alone could prevent obesity.
The body weights of the db/db and Delta/Delta animals
are much higher than that of the WT animals, and the body
weights are not different between the db/db and Delta/
Delta animals. Similarly, the measurement of food intake
in these animals reveals that the db/db and Delta/Delta
animals eat similar amounts of food and that the amount
they each consume is much greater than that for the WT
animals. Consequently, while the WT animals have rela-
tively low body fat, the db/db and Delta/Delta animals
exhibit similarly elevated fat content; both are close to 50%
body fat. These data suggest that Jak2 signaling alone, in




FIG. 2. Leptin receptor–expressing neurons in the mouse hypothalamus. Expression of green ﬂuorescent protein (GFP) (shown in white) marks
leptin receptor neurons in a coronal section of the brain of transgenic leptin receptor-GFP mice. Note the presence of multiple groups of leptin
receptor neurons in the hypothalamus, but the presence of few leptin receptor neurons in other parts of the brain, including the motor cortex.
(A high-quality digital representation of this ﬁgure is available in the online issue.)
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What about glucose homeostasis? While blood glucose
levels in the WT animals remain low for the duration of the
study, the levels in the db/db mice are elevated even at very
young ages. In contrast, the blood glucose levels in young
Delta/Delta mice, although they are a bit higher than the
normal animals, are lower than in the db/db mice. Overall,
these data suggest that while Jak2 alone contributes little
to the regulation of feeding and body weight, Jak2 signal-
ing makes a modest contribution to the control of blood
glucose levels.
Because the body weight and adiposity of the db/db and
Delta/Delta animals are similar, the improvement in glu-
cose homeostasis in the Delta/Delta relative to db/db mice
represents a direct leptin effect, not a difference as a result
of body fat levels. It is also important to note that Jak2
signaling alone is insufﬁcient to mediate perfectly normal
glucose homeostasis. This suggests that the tyrosine phos-
phorylation sites on the tail of the leptin receptor and the
downstream signals that they control contribute impor-
tantly to the regulation of glucose homeostasis, in addition
to mediating the effects of leptin on feeding and energy
balance.
In order to determine the tyrosine phosphorylation site
or sites on the tail of the leptin receptor that mediate these
effects, we examined mice expressing single point muta-
tions of the leptin receptor. The ﬁrst of the mouse lines is
mutant for Tyr985, and so this leptin receptor fails to
recruit SHP2 and SOCS3.
What we found in these animals was essentially the
opposite of a db/db animal. When eating a diet of normal
mouse chow (this is the mouse diet equivalent of shredded
wheat or kashi cereal), the mutant animals demonstrate a
trend toward decreased body weight compared with the
normal mice. Furthermore, if one feeds these animals a
high-fat diet (this is similar to feeding them donuts or fast
food), the WT animals crave this food, overeat, and gain a
lot of weight. In contrast, the mutant animals gain rela-
tively little weight. In fact, when one looks at food intake
right after these animals are switched onto the high-fat
diet, it turns out that the mutant animals eat substantially
less of the high-fat food than the normal animals. These
data suggest that, far from being compromised in their
ability to respond to leptin, these mutant animals might
actually be ultrasensitive to leptin.
To test this directly, we gave the mice a tiny amount of
leptin over 3 days and followed their body weight. The
amount of leptin that we used was so small that the WT
animals lost essentially no weight. In contrast, the mutant
animals lost 6–7% of their body weight over the 3-day
treatment period. Additionally, glucose homeostasis is
normal in this line of mutant animals.
Thus, the mice mutant for Tyr985 and SHP2/SOCS3
signaling exhibit no defects in the metabolic actions of
leptin, suggesting that this residue does not play a role in
mediating the effects of leptin on feeding and glucose
homeostasis. In fact, these animals are actually more
sensitive to leptin, suggesting that (similar to our ﬁndings
in our initial signaling studies in cultured cells) Tyr985 acts
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FIG. 3. Mutant leptin receptors expressed in mouse models. See text for details.
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In addition, because Tyr985 is not doing much in this
regard, the big guns of leptin receptor action on feeding
and glucose homeostasis must be Tyr1077 and/or Tyr1138
and STAT3 and/or STAT5 signaling.
We thus examined the mice expressing the leptin recep-
tor mutant for Tyr1077, which is impaired for STAT5
signaling. Compared with the WT animals, the STAT5
mutants tend to have a very small increase in body weight.
Similarly, when we examine feeding, the trend line for the
mutants lies very slightly above that for WT animals but is
not signiﬁcantly different. When we examine body fat,
however, this more sensitive measure reveals a modest,
but signiﬁcant, increase in body fat in the STAT5 mutants
compared with the WT mice. Thus, STAT5 plays a minor
role in the regulation of body weight by leptin.
What about glucose homeostasis? In this case, there is
no difference in blood glucose between the WT and mutant
mice, and there is no signiﬁcant difference in circulating
insulin levels between the WT and mutant mice. In fact,
even in an insulin tolerance test, which examines how
sensitively the mice respond to insulin by testing the fall in
glucose after insulin administration, the WT and mutant
mice respond similarly.
All of these data reveal that Tyr1077 makes a very small
contribution to the regulation of feeding and body fat, but
is not required for the maintenance of normal glucose
homeostasis. Thus, these data suggest that STAT3 signal-
ing will be very important for the regulation of feeding,
adiposity, and the regulation of glucose homeostasis.
In our ﬁnal mutant leptin receptor, we disrupted
Tyr1138, preventing the leptin receptor from engaging
STAT3. From the very ﬁrst time we saw these animals, it
was clear that we had interfered with an important leptin
signal. Figure 4 shows a picture of a 6-month-old leptin
receptor-STAT3 signaling mutant mouse. This animal is
very large and very interested in food. While a WT animal
of this age would weigh about 30 g, this mouse weighs in
at three and one-half times that much—over 108 g.
Comparing these animals more quantitatively with nor-
mal and db/db mice, one can see that the db/db animals
weigh much more than the WT animals and that these
STAT3 mutant animals weigh almost as much as the db/db
animals. Furthermore, while the fat content of the WT
animals is quite low, the db/db animals are almost 50% fat.
The STAT3 mutant animals are also much fatter than the
WT mice, almost as high in fat content as the db/db
animals. These data suggest the following: 1) STAT3
signaling is very important for the regulation of body
weight and adiposity, and 2) although STAT3 is important,
it does not mediate 100% of leptin action because these
mutant mice are not quite as heavy or overweight as the
db/db animals.
In reference to food intake, the WT animals eat about
3.5 g of food per day, while the db/db and STAT3 mutant
animals eat 6–7 g per day. Examining glucose homeostasis
in these animals is complicated by the amount they eat and
by their obesity as obesity promotes insulin resistance.
Therefore, we not only examined blood glucose levels in
the ad libitum fed animals, but also in the so-called pair-fed
animals that were fed the amount of food eaten by the WT
animals each day. The WT animals, of course, had normal
blood glucose for the duration of the study. The db/db
animals that were eating as much food as they liked
displayed a very rapid increase in blood glucose levels.
Mutant animals that lack STAT3 signaling also displayed
an increase in blood glucose levels as they aged, although
not nearly to the level of the db/db animals. The pair-fed
db/db animals, which ate the same amount of food as the
WT mice, demonstrated lower blood glucose than the
freely feeding db/db animals—similar to the freely feeding
STAT3 mutants. In contrast, if one pair feeds the STAT3
mutant animals, this normalizes their blood glucose.
These data show that Tyr11383STAT3 signaling is very
important for the regulation of feeding and also suggest
that this signal is important for the regulation of glucose
homeostasis, although a great deal of this effect of STAT3
on blood glucose is secondary to the control of feeding
and adiposity. When these STAT3 mutant animals become
obese, they also become insulin resistant, causing blood
glucose levels to rise.
Overall the analysis of these mouse lines has revealed
the intracellular signaling mechanisms by which the leptin
receptor regulates whole body physiology. Jak2 makes a
modest contribution to the regulation of glucose ho-
meostasis; Tyr1138 and STAT3 signaling plays a crucial
role in the regulation of feeding and adiposity and thereby
the control of glucose homeostasis. Tyr1077 and STAT5
make a modest contribution to the regulation of feeding,
and together STAT3 and STAT5 represent the major
contributors to the regulation of energy homeostasis. In
contrast, Tyr985 does not mediate important signals to
suppress feeding and adiposity, but rather its major role in
vivo is to mediate feedback inhibition, which limits leptin
receptors signaling.
The next question we posed is, how do each of these
FIG. 4. Mouse mutant for leptin receptor Tyr1138.
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homeostasis, and the like? The main problem we face in
addressing this question is essentially that the brain is not
the liver. That is, although the liver is an essentially
homogenous organ comprised of one major cell type, we
cannot study leptin action in the brain as if all of the brain
cells are the same.
Each type of brain cell is specialized, contains a distinct
set of neurotransmitter chemicals, and communicates
with only a few other brain cells to perform speciﬁc
functions. As seen in Fig. 2, while the leptin receptor is not
expressed everywhere in the brain, there are many differ-
ent groups of leptin receptor expressing neurons in the
brain—each of which presumably subserves a different
function. Because we currently know very little about
most of these leptin-responsive neurons, we need to
determine the roles for each of these sets of neurons in
leptin action.
This article also covers two different groups of leptin
receptor–expressing neurons—the ﬁrst of these lies in the
lateral hypothalamic area (LHA). Why study the LHA?
First, overeating and obesity represent major contributors
to the onset of type 2 diabetes. Second, the LHA is known
to regulate the mesolimbic dopamine system. The me-
solimbic dopamine system is the part of the brain that
regulates the desire for natural rewards (such as food and
sex), along with artiﬁcial rewards, such as drugs of abuse.
The seat of the mesolimbic dopamine system is a part of
the brain called the ventral tegmental area (VTA), where
lie a set of neurons that contain the neurotransmitter
dopamine. Dopamine coming from these VTA neurons
regulates “wanting” for rewarding things. The LHA inter-
acts with the mesolimbic dopamine system to control
feeding and drug taking. Therefore, we reasoned that the
leptin receptor neurons in the LHA are poised to regulate
an important participant in eating and overeating.
But is that what the lateral hypothalamic leptin receptor
neurons actually do? To answer this question, Gina Lein-
ninger, a stellar postdoc in the lab, performed an experi-
ment where she administered a very small amount of
leptin directly into the LHA of the ob/ob mice, so that these
were the only neurons in the brain that would respond to
the leptin. This small dose of leptin decreased the amount
of food that the mice ate and decreased their body weight
over 24 h.
We also looked to see what was happening in the brain
of these ob/ob animals following the administration of
leptin into the LHA. Now, since we were only administer-
ing the leptin on one side of the brain, we would only
expect to see one side of the brain responding to the
leptin. Indeed, leptin increased the expression of tyrosine
hydroxylase (the enzyme that makes dopamine) and in-
creased the amount of dopamine in the mesolimbic sys-
tem, but only on the side of the brain that received leptin.
Thus, leptin acts on the LHA leptin receptor neurons,
which we have shown to project to the VTA, thereby
regulating the amount of dopamine in the mesolimbic
dopamine system and contributing to the control of feed-
ing and body weight.
The next and ﬁnal area that I discuss here is a part of the
hypothalamus called the ventral premammillary nucleus
(PMv). In this case, we chose to study this region because
it contains a very large number of leptin receptor neurons,
and we reasoned it must be important if there are so many
leptin responsive neurons. Other interesting things about
the PMv include that it is sexually dimorphic—there are
differences in the neurons between male and female mice.
Indeed, the PMv in male mice expresses the testosterone
receptor, and it projects more strongly in male than in
female mice to a part of the brain called the paraventricu-
lar nucleus of the hypothalamus (PVH). The PVH, although
it contains only few leptin receptor neurons, is a major site
for controlling food intake and metabolism.
We thus hypothesized that PMv leptin receptor neurons
would be important for the control of energy balance and
glucose homeostasis and that it would be more important
for these things in male than in female mice. This sug-
gested an experiment to remove the leptin receptor from
the PMv and see what happens to obesity and diabetes in
male and female mice. So that is exactly what Rebecca
Leshan, a superb graduate student in my lab, did. Com-
pared with the WT animals, db/db female mice have a very
high body weight. The animals lacking leptin receptor in
the PMv only (PMvKO mice) also have increased body
weight compared with that in normal controls, but their
body weight is not as great as that seen for the db/db
female mice.
Compared with the WT males, the db/db male mice also
demonstrate increased body weight. In this case, however,
the PMvKO male mice have body weights indistinguish-
able from those of the db/db male mice. Similarly, food
intake is dramatically increased in the db/db female mice
compared with the WT animals, and although it is higher in
the PMvKO female mice than in the controls, these mice
eat far less than the db/db female mice. Again, in the male
mice, food intake in the PMvKO mice is higher than in the
control animals, but the PMvKO male mice eat as much
food as the db/db mice that have no leptin receptor
anywhere in the brain.
What about glucose homeostasis? Blood glucose is
normal in the WT female mice and elevated in the db/db
female mice, but there is little increase in blood glucose in
the female PMvKO animals. Once again, the male mice
are a different story: blood glucose levels are elevated in
the db/db male compared with normal animals, and the
PMvKO male mice exhibit similarly elevated blood glucose
levels. As for glucose, insulin levels in the PMvKO female
mice are somewhat elevated, suggesting some insulin
resistance, but they remain far below the levels seen in the
db/db female mice. However, in male mice, insulin levels
are similarly elevated in the PMv knockout and db/db male
mice.
Together, these data demonstrate that leptin action via
PMv leptin receptor neurons in the male mice is crucial to
the regulation of food intake, body weight, and glucose
homeostasis. In the female mice, on the other hand, the
PMv contributes to each of these aspects of food intake,
body weight, and glucose metabolism, but to a much lesser
extent than in the male mice. What might then leptin
action via the PMv leptin receptor neurons be doing in the
female mice? Earlier, I mentioned that leptin is an impor-
tant regulator of endocrine function, and one of the
endocrine functions that leptin controls is fertility. As it
turns out, there is a major defect in reproductive function
in the PMvKO female mice. Rebecca Leshan examined the
onset of puberty in these animals and found that essen-
tially all WT animals enter puberty by the time they are 50
or 60 days old; in contrast, the PMvKO female mice enter
puberty at a much slower rate, and almost 75% of them fail
to enter full puberty at all.
Thus, the leptin receptor neurons in the male and female
PMv perform somewhat overlapping but somewhat dis-
M.G. MYERS JR.
diabetes.diabetesjournals.org DIABETES, VOL. 59, NOVEMBER 2010 2713tinct functions: in male mice, these neurons play a domi-
nant role in the regulation of metabolism, while in female
mice, the role these neurons play in the regulation of body
weight and glucose homeostasis is more minor, and these
neurons play a major role in the regulation of fertility.
We have only begun to scratch the surface: there is a lot
more work to be done in the system because there are
many different types of leptin receptor neurons in places
that we and others have only just begun to think about. For
each of these sets of neurons, we need to determine what
brain areas they control, what neurotransmitters they use,
and how they contribute to energy balance and glucose
homeostasis—just as we have done for the LHA and the
PMv. We also need to understand the roles for speciﬁc
leptin receptor signals in the regulation of each of these
neuronal populations and to contemplate how these neu-
rons and the speciﬁc signals that control them might be
targeted for the therapy of obesity and type 2 diabetes.
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